PRADC1P1

Across TCGA pan-cancer cohorts, PRADC1P1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PRADC1P1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PRADC1P1 RNA is repressed in tumor relative to normal tissue. In most cancer types PRADC1P1 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and KIRC are the cancer types where PRADC1P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRADC1P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.439	<.001	7	view →
LUSC	Female	All	−0.452	.026	2	view →
KIRC	All	All	−0.220	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PRADC1P1–THCA

Open the THCA breakdown →